Anticipate generic drug launch
Find generic entry opportunities
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Proactively manage your pharmacy inventory
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
|Title:||(R)-3-(2-deox y-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,][1,3]diaz epin-8-ol|
|Abstract:||Essentially pure (R)-3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[ 4,5-d][1,3]-diazepin-8-ol and the process for the production of (R)-3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[ 4,5-d][1,3]diazepin-8-ol by inoculating an aqueous nutrient medium, preferably containing sources of assimilable carbon and nitrogen and added inorganic salt and having a pH between about 6 and 8, with a (R)-3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[ 4,5-d][1,3]diazepin-8-ol producing strain of Streptomyces antibioticus, such as the strain corresponding to NRRL 3238, conducting a fermentation under aseptic aerobic conditions at a temperature between about 20 and 45.degree.C. until a substantial quantity of (R)-3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo- [4,5-d][1,3]diazepin-8-ol is formed, and isolating the desired product from the fermentation mixture are disclosed. The (R)-3-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[ 4,5-d][1,3]diazepin-8-ol potentiates the activity of 9-(.beta.-D-arabinofuranosyl)adenine as an antiviral agent that is active in vitro and in vivo against DNA viruses such as herpes and vaccinia viruses.|
|Inventor(s):||Ryder; Albert (Detroit, MI), Dion; Henry W. (Detroit, MI), Woo; Peter W. (Ann Arbor, MI), Howells; John D. (Grosse Pointe Woods, MI)|
|Assignee:||Parke, Davis & Company (Detroit, MI)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.